Prevalence of atopic dermatitis in the adolescent population of Catalonia (Spain)
Main Article Content
Keywords
atopic dermatitis, epidemiological study, population-based, prevalence, severity, comorbidities, total serum IgE
Abstract
Background: Studies on the prevalence of atopic dermatitis (AD) for the adolescent cohort in general-based large populations are scarce worldwide. We performed a retrospective population--based observational cohort study of 76,665 adolescent patients diagnosed with AD in Catalonia (Spain). We studied the prevalence of AD by age, gender, disease severity, comorbidities, serum total immunoglobulin E (tIgE) and appropriate medical treatment (AMT) for the Catalan population.
Methods: Adolescent individuals (12–17 years) diagnosed with AD by medical records at different health care levels (primary, hospital, emergency) from the Catalan Health System (CHS) were included. Statistical analyses evaluated sociodemographic characteristics, prevalence, comorbidities, serum tIgE and AMT.
Results: The overall diagnosed AD prevalence in the adolescent Catalan population (76,665) was 16.9%, being higher for the non-severe (16.7%) than for the severe (0.2%) populations. Topical corticosteroids were the most prescribed drug (49.5%), and the use of all prescribed treatments was higher in severe AD patients, especially systemic corticosteroids (49.7%) and immunosuppressants (45.4%). AD patients had, on average, a serum tIgE of 163.6 KU/L, which was higher for severe than non-severe disease (155.5 KU/L vs 101.9 KU/L, respectively). Allergic rhinitis (15.0%) and asthma (13.5%) were among the most frequent comorbid respiratory and allergy diseases.
Conclusions: This is the first Spanish study reporting the overall diagnosed prevalence for a large-scale adolescent cohort (12–17 years old) from Catalonia. It provides new and robust evidence of AD’s prevalence and related characteristics in this region.
References
2. Ring J, Przybilla B, Ruzicka T, eds. Handbook of atopic eczema. Springer Science & Business Media: Germany 2006, 484 p.
3. Serra-Baldrich E, de Frutos JO, Jáuregui I, Armario-Hita JC, Silvestre JF, Herraez L, et al. Changing perspectives in atopic dermatitis. Allergol Immunopathol (Madr). 2018;46(4):397–412. 10.1016/j.aller.2017.07.002
4. Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54–56. 10.1111/all.13954
5. Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Busse WW, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions.” J Allergy Clin Immunol. 2019;143(3):894–913. 10.1016/j.jaci.2019.01.003
6. Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta--analysis. J Am Acad Dermatol. 2016 Oct;75(4):681–687.e11. 10.1016/j.jaad.2016.05.028
7. Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021 Apr;126(4):417–428.e2. 10.1016/j.anai.2020.12.020
8. Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125–138. 10.1016/s0091-6749(99)70536-1
9. Sicras-Mainar A, Navarro-Artieda R, Armario-Hita JC. Severe atopic dermatitis in Spain: a real-life observational study. Ther Clin Risk Manag. 2019;15:1393–1401. 10.2147/TCRM.S226456
10. Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022 Apr 26;2(5):100131. 10.1016/j.xjidi.2022.100131
11. Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1212–1223.e6. 10.1016/j.jaip.2020.12.059
12. Stalder JF, Taïeb A, Atherton DJ, Bieber P, Bonifazi E, Broberg A, et al. Severity scoring of atopic dermatitis: the SCORAD index: consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31. 10.1159/000247298
13. Sicras-Mainar A, Navarro-Artieda R, Sánchez L, Sastre J. Prevalence of severe atopic dermatitis in adults in 3 areas of Spain. J Investig Allergol Clin Immunol. 2018;28(3):195–197. 10.18176/jiaci.0234
14. Atwal S, Ong PY. Elevated serum total IgE is associated with eczema exacerbation in children hospitalized for atopic-dermatitis. Pediatr Dermatol. 2023;40(2):301–304. 10.1111/pde.15245
15. Español GI. Prevalencia de síntomas sugestivos de rinitis alérgica y de dermatitis atópica en adolescentes (Estudio ISAAC España). An Esp Pediatr. 1999;51(4):369–376.
16. Suda K, Akagi T, Ikeda HO, Kameda T, Hasegawa T, Miyake M, et al. Atopic dermatitis as a risk factor for severe visual field loss in youth-a retrospective cohort study of glaucoma under steroid treatment. Graefes Arch Clin Exp Ophthalmol. 2021;259(1):129–136. 10.1007/s00417-020-04925-z
17. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007 Feb;56(2):211–216. 10.1016/j.jaad.2006.05.073
18. Kosse RC, Bouvy ML, Daanen M, de Vries TW, Koster ES. Adolescents’ perspectives on atopic dermatitis treatment--experiences, preferences, and beliefs. JAMA Dermatol. 2018;154(7):824–827. 10.1001/jamadermatol.2018.1096
19. Wittig HJ, Belloit J, De Fillippi I, Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol. 1980;66(4):305–313. 10.1016/0091-6749(80)90026-3
20. Sehgal VN, Srivastava G, Aggarwal AK, Saxena D, Chatterjee K, Khurana A. Atopic dermatitis: a cross-sectional (descriptive) study of 100 cases. Indian J Dermatol. 2015;60(5):519. 10.4103/0019-5154.164412
21. Vaneckova J, Bukač J. The severity of atopic dermatitis and the relation to the level of total IgE, the onset of atopic dermatitis and family history about atopy. Food Agric Immunol. 2016;27(5):734–741. 10.1080/09540105.2016.1183598
22. Rhodes HL, Sporik R, Thomas P, Holgate ST, Cogswell JJ. Early life risk factors for adult asthma: a birth cohort study of at-risk subjects. J Allergy Clin Immunol. 2001;108(5):720–725. 10.1067/mai.2001.119151
23. Schmitt J, Chen C-M, Apfelbacher C, Romanos M, Lehmann I, Herbarth O, et al. Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study LISAplus Allergy. 2011;66(3):404–411. 10.1111/j.1398-9995.2010.02487
24. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428–433. 10.1016/j.jaci.2012.10.041
25. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25. 10.1016/j.jid.2016.08.022
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.